Detection of secondary binding sites in proteins using fragment screening

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 52, 2015, Pages 15910-15915

  Ludlow, R Frederick ^a   Verdonk, Marcel L ^a   Saini, Harpreet K ^a   Tickle, Ian J ^a   Jhoti, Harren ^a  

^a ASTEX PHARMACEUTICALS   (United Kingdom)

Author keywords

Fragment based drug design; Protein function; Protein structure; X ray crystallography

Indexed keywords

PROTEIN; PROTEIN BINDING;

ALLOSTERISM; ARTICLE; BINDING SITE; CRYSTAL STRUCTURE; FRAGMENT SCREENING; LIGAND BINDING; MOLECULAR DYNAMICS; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN STRUCTURE; SEQUENCE ANALYSIS; X RAY CRYSTALLOGRAPHY; ALGORITHM; CHEMISTRY; HUMAN; METABOLISM; MOLECULAR MODEL; PROCEDURES; PROTEIN DOMAIN;

ALGORITHMS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; HUMANS; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN INTERACTION MAPPING; PROTEINS;

EID: 84952690377     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1518946112     Document Type: Article

References (43)

1. Hardy JA, Wells JA (2004) Searching for new allosteric sites in enzymes. Curr Opin Struct Biol 14(6):706-715.
2. Conn PJ, Christopoulos A, Lindsley CW (2009) Allosteric modulators of GPCRs: A novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 8(1):41-54.
3. Nussinov R, Tsai CJ (2013) Allostery in disease and in drug discovery. Cell 153(2):293-305.
4. Hauske P, Ottmann C, Meltzer M, Ehrmann M, Kaiser M (2008) Allosteric regulation of proteases. ChemBioChem 9(18):2920-2928.
5. Langmead CJ, Christopoulos A (2014) Functional and structural perspectives on allosteric modulation of GPCRs. Curr Opin Cell Biol 27:94-101.
6. Lewis JA, Lebois EP, Lindsley CW (2008) Allosteric modulation of kinases and GPCRs: Design principles and structural diversity. Curr Opin Chem Biol 12(3):269-280.
7. Ohren JF, et al. (2004) Structures of human MAP kinase kinase 1(MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol 11(12):1192-1197.
8. Di Santo R (2014) Inhibiting the HIV integration process: Past, present, and the future. J Med Chem 57(3):539-566.
9. Adrián FJ, et al. (2006) Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol 2(2):95-102.
10. Nussinov R, Tsai CJ (2012) The different ways through which specificity works in orthosteric and allosteric drugs. Curr Pharm Des 18(9):1311-1316.
11. Grimsby J, Berthel SJ, Sarabu R (2008) Glucokinase activators for the potential treatment of type 2 diabetes. Curr Top Med Chem 8(17):1524-1532.
12. Kozakov D, et al. (2015) The FTMap family of web servers for determining and characterizing ligand-binding hot spots of proteins. Nat Protoc 10(5):733-755.
13. Capra JA, Laskowski RA, Thornton JM, Singh M, Funkhouser TA (2009) Predicting protein ligand binding sites by combining evolutionary sequence conservation and 3D structure. PLoS Comput Biol 5(12):e1000585.
14. LaPlante SR, et al. (2014) Integrated strategies for identifying leads that target the NS3 helicase of the hepatitis C virus. J Med Chem 57(5):2074-2090.
15. Bowman GR, Geissler PL (2012) Equilibrium fluctuations of a single folded protein reveal a multitude of potential cryptic allosteric sites. Proc Natl Acad Sci USA 109(29):11681-11686.
16. Murray CW, Rees DC (2009) The rise of fragment-based drug discovery. Nat Chem 1(3):187-192.
17. Murray CW, Verdonk ML, Rees DC (2012) Experiences in fragment-based drug discovery. Trends Pharmacol Sci 33(5):224-232.
18. Saalau-Bethell SM, et al. (2012) Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function. Nat Chem Biol 8(11):920-925.
19. Chaneton B, et al. (2012) Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature 491(7424):458-462.
20. Saalau-Bethell SM, et al. (2014) Crystal structure of human soluble adenylate cyclase reveals a distinct, highly flexible allosteric bicarbonate binding pocket. ChemMedChem 9(4):823-832.
21. Kleinboelting S, et al. (2014) Crystal structures of human soluble adenylyl cyclase reveal mechanisms of catalysis and of its activation through bicarbonate. Proc Natl Acad Sci USA 111(10):3727-3732.
22. Bauman JD, et al. (2013) Detecting allosteric sites of HIV-1 reverse transcriptase by X-ray crystallographic fragment screening. J Med Chem 56(7):2738-2746.
23. Jahnke W, et al. (2010) Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery. Nat Chem Biol 6(9):660-666.
24. Jahnke W, et al. (2010) Binding or bending: Distinction of allosteric Abl kinase agonists from antagonists by an NMR-based conformational assay. J Am Chem Soc 132(20):7043-7048.
25. Zhang J, et al. (2010) Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 463(7280):501-506.
26. Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM (2013) K-Ras (G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503(7477):548-551.
27. Hartshorn MJ, et al. (2005) Fragment-based lead discovery using X-ray crystallography. J Med Chem 48(2):403-413.
28. Mooij WT, et al. (2006) Automated protein-ligand crystallography for structure-based drug design. ChemMedChem 1(8):827-838.
29. Hendlich M, Rippmann F, Barnickel G (1997) LIGSITE: Automatic and efficient detection of potential small molecule-binding sites in proteins. J Mol Graph Model 15(6):359-363, 389.
30. Rothweiler U, et al. (2015) Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors. Eur J Med Chem 94:140-148.
31. Jeffrey PD, et al. (1995) Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 376(6538):313-320.
32. Betzi S, et al. (2011) Discovery of a potential allosteric ligand binding site in CDK2. ACS Chem Biol 6(5):492-501.
33. Rodina A, et al. (2013) Identification of an allosteric pocket on human hsp70 reveals a mode of inhibition of this therapeutically important protein. Chem Biol 20(12):1469-1480.
34. Howard S, et al. (2013) Fragment-based discovery of 6-azaindazoles as inhibitors of bacterial DNA ligase. ACS Med Chem Lett 4(12):1208-1212.
35. Gesell J, McCoy M, Senior M, Wang Y-S, Wyss D (2006) Modern Magnetic Resonance, ed Webb GA (Springer, Dordrecht, The Netherlands), pp 1419-1428.
36. Tharmalingam S, Burns AR, Roy PJ, Hampson DR (2012) Orthosteric and allosteric drug binding sites in the Caenorhabditis elegans mgl-2 metabotropic glutamate receptor. Neuropharmacology 63(4):667-674.
37. Hudson JW, Golding GB, Crerar MM (1993) Evolution of allosteric control in glycogen phosphorylase. J Mol Biol 234(3):700-721.
38. Bairoch A, et al. (2005) The Universal Protein Resource (UniProt). Nucleic Acids Res 33(Database issue):D154-D159.
39. Katoh K, Misawa K, Kuma K, Miyata T (2002) MAFFT: A novel method for rapid multiple sequence alignment based on fast Fourier transform. Nucleic Acids Res 30(14):3059-3066.
40. McConkey BJ, Sobolev V, Edelman M (2002) Quantification of protein surfaces, volumes and atom-atom contacts using a constrained Voronoi procedure. Bioinformatics 18(10):1365-1373.
41. Yuan Z, Zhao J, Wang ZX (2003) Flexibility analysis of enzyme active sites by crystallographic temperature factors. Protein Eng 16(2):109-114.
42. Yang CY, Wang R, Wang S (2005) A systematic analysis of the effect of small-molecule binding on protein flexibility of the ligand-binding sites. J Med Chem 48(18):5648-5650.
43. Howlin B, Butler SA, Moss DS, Harris GW, Driessen HPC (1993) TLSANL: TLS parameteranalysis program for segmented anisotropic refinement of macromolecular structures. J Appl Cryst 26:622-624.